Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications |
| |
Authors: | Kalra Sanjay Unnikrishnan Ambika G Agrawal Navneet Singh Anupam K |
| |
Institution: | Bharti Hospital, Karnal, Haryana, India. brideknl@gmail.com |
| |
Abstract: | The dipeptidyl peptidase-4 (DPP-4) inhibitors linagliptin, sitagliptin, saxagliptin, vildagliptin and alogliptin are being developed and have been approved for the treatment of type-2 diabetes. These agents may be used either as monotherapy for the treatment of type-2 diabetes or in combination with other anti-diabetic drugs. The present review highlights the use of linagliptin and other new (DPP-4) inhibitors in the management of type-2 diabetes. The review also highlights advantages, comparative pharmacokinetic, safety profile and other potential uses including potential newer indications of DPP-4 inhibitors and relevant patents. The other potential uses that are not restricted to diabetes include obesity, cardiovascular disease, neurological disease, hepatobiliary disease, wound healing, and other inflammatory illnesses. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|